Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01787474 · ClinicalTrials.gov registry record · Phase 1

Donor Natural Killer Cells in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

A Phase 1 study of Refractory Acute Myeloid Leukemia and Recurrent Adult Acute Myeloid Leukemia, sponsored by M.D. Anderson Cancer Center.

Completed
Registry status
Phase 1
Development phase
30
Enrollment target
1
Study location

NCT01787474: Completed Phase 1 study of Refractory Acute Myeloid Leukemia and Recurrent Adult Acute Myeloid Leukemia, sponsored by M.D. Anderson Cancer Center.

NCT01787474 is a Phase 1 study of Refractory Acute Myeloid Leukemia and Recurrent Adult Acute Myeloid Leukemia that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 30 participants, below the 47-participant average among 63 other Refractory Acute Myeloid Leukemia trials with a reported enrollment target (36% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01787474, a Phase 1 study of Refractory Acute Myeloid Leukemia and Recurrent Adult Acute Myeloid Leukemia, has completed, sponsored by M.D. Anderson Cancer Center.

COMPLETED
Registry status
Phase 1
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

This phase I/II trial studies the side effects and best dose of donor natural kill cells and to see how well they work in treating patients with acute myeloid leukemia that does not respond to treatment (refractory) or has come back after a period of improvement (relapsed). Giving natural killer cells after high dose chemotherapy may boost the patient's immune system by helping it see the remaining cancer cells as not belonging in the patient's body and causing it to destroy them (called graft-versus-tumor effect).

Conditions Studied

Refractory Acute Myeloid Leukemia Recurrent Adult Acute Myeloid Leukemia

Interventions

  • OTHER Laboratory Biomarker Analysis
  • DRUG Cytarabine
  • BIOLOGICAL Filgrastim
  • DRUG Fludarabine Phosphate
  • BIOLOGICAL Filgrastim-sndz

Study Locations (1)

Texas

  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2014-05-19
Est. Completion 2021-06-17
Phase Phase 1

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01787474

The ClinicalTrials.gov registry entry for NCT01787474 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 47-participant average among 63 other Refractory Acute Myeloid Leukemia trials with a reported enrollment target (36% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Refractory Acute Myeloid Leukemia appearing as the primary indexed condition, and to 5 interventions - of which Laboratory Biomarker Analysis is the first listed.

NCT01787474 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT01787474 about?

NCT01787474 is a clinical study titled "Donor Natural Killer Cells in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia". This phase I/II trial studies the side effects and best dose of donor natural kill cells and to see how well they work in treating patients with acute myeloid leukemia that does not respond to treatment (refractory) or has come back after a period of improvement (relapsed). Giving natural killer cel...

What is the current status of trial NCT01787474?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2014-05-19. Estimated completion is 2021-06-17.

What conditions does trial NCT01787474 study?

This clinical trial studies the following conditions: Refractory Acute Myeloid Leukemia, Recurrent Adult Acute Myeloid Leukemia.

What interventions are being tested in trial NCT01787474?

The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Cytarabine (DRUG), Filgrastim (BIOLOGICAL), Fludarabine Phosphate (DRUG), Filgrastim-sndz (BIOLOGICAL).

Who is sponsoring clinical trial NCT01787474?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01787474 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Refractory Acute Myeloid Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Refractory Acute Myeloid Leukemia

All registered trials for this condition

Recurrent Adult Acute Myeloid Leukemia

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.